Table 1.
Demographic and clinical data of patients.
| Parameter | Patients (n = 292) |
| Age (year) | 58.3 ± 13.6 (20 to 89)∗ |
| Gender | No (%) |
| Female | 147 (50.3) |
| Male | 145 (49.7) |
| Diagnosis | No (%) |
| NTG | 125 (42.8) |
| POAG | 82 (28.1) |
| PACG | 50 (17.1) |
| OHT | 17 (5.8) |
| Others | 18 (6.2) |
| No. of glaucoma medications | No (%) |
| 1 (Brimonidine monotherapy) | 177 (60.6) |
| 2† | 64 (21.9) |
| 3‡ | 20 (6.8) |
| 4§ | 31 (10.6) |
| BAK | |
| Without BAK | 162 (55.5) |
| With BAK | 130 (44.5) |
∗
Data presented as mean ± standard deviation (minimum to maximum).
†
Brimonidine combined with any one of β-blockers, carbonic anhydrase inhibitors (CAI), or prostaglandin analogues (PGA).
‡
Brimonidine combined with any two of β-blockers, CAI, or PGA.
§
Brimonidine combined with β-blockers, CAI and PGA.
(β-blockers included betaxolol, carteolol and timolol. CAI included dorzolamide and brinzolamide. PGA included latanoprost, travoprost, bimatoprost and tafluprost.)
BAK = benzalkonium chloride, NTG = normal tension glaucoma, OHT = ocular hypertension, PACG = primary angle closure glaucoma, POAG = primary open angle glaucoma.